This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bar-Ner, M. Articles by Samid, D. Search for Related Content PubMed PubMed Citation Articles by Bar-Ner, M. Articles by Samid, D.

Phenylbutyrate Induces Cell Differentiation and Modulates Epstein-Barr Virus Gene Expression in Burkitt’s Lymphoma Cells¹

Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 [M. B-N., I. T. M.]; Pathology Department, Clinical Center, NIH, Bethesda, Maryland 20892 [M. T.]; and University of Virginia Health Sciences Center, Charlottesville, Virginia 22908 [A. T., D. S.]

Although Burkitt’s lymphoma (BL) is a readily treated malignancy, recurrences, as well as disease arising in immunosuppressed patients, are notoriously resistant to conventional therapeutic approaches. The EBV is associated with a significant proportion of these lymphomas that evade immune surveillance through decreased expression of both viral and cellular antigens. Increasing the immunogenicity of BL cells may, therefore, represent a potentially beneficial therapeutic maneuver. Using in vitro models of EBV-transformed lymphoblastoid as well as BL cell lines, we demonstrate increased expression of genes coding for HLA class I and EBV latent proteins by the differentiation inducer phenylbutyrate (PB). The aromatic fatty acid also caused cytostasis associated with sustained declines in c-myc expression, a direct antitumor effect that was independent of the EBV status. We conclude, therefore, that differentiation therapy of BL with PB may lead to growth arrest with increased tumor immunogenicity in vivo. The findings may have clinical relevance because the in vitro activity has been observed with PB concentrations that are well tolerated and nonimmunosuppressive in humans, a desirable feature for the different patient populations afflicted with this disease.

This article has been cited by other articles:

				X.-N. Li, S. Parikh, Q. Shu, H.-L. Jung, C.-W. Chow, L. Perlaky, H.-C. E. Leung, J. Su, S. Blaney, and C. C. Lau Phenylbutyrate and Phenylacetate Induce Differentiation and Inhibit Proliferation of Human Medulloblastoma Cells Clin. Cancer Res., February 1, 2004; 10(3): 1150 - 1159. [Abstract] [Full Text] [PDF]

				S. A. McGrath-Morrow and J. L. Stahl G1 Phase Growth Arrest and Induction of p21Waf1/Cip1/Sdi1 in IB3-1 Cells Treated with 4-Sodium Phenylbutyrate J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 941 - 947. [Abstract] [Full Text]